Form 4: HRT Financial LP Adjusts Stake in Clearmind Medicine
Statement of Changes in Beneficial Ownership
HRT Financial LP reported recent open market purchases and sales of Clearmind Medicine Inc. common stock.
Summary
- HRT Financial LP, a 10% owner, executed transactions in Clearmind Medicine Inc. (CMND) common stock.
- On June 10, 2026, the reporting person purchased 2,159,052 shares at an average price of $0.153.
- On June 11, 2026, the reporting person sold 225,191 shares at an average price of $0.123.
- Following these transactions, the reporting person holds 1,838,075 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as neutral; while the net acquisition is positive, the immediate partial sale suggests a lack of long-term conviction or a purely technical trading strategy.
Positives
- Significant accumulation of shares by a 10% institutional owner indicates potential confidence in the issuer's long-term prospects.
Negatives
- The reporting person engaged in a partial sell-off of shares immediately following the large purchase, suggesting short-term trading activity or profit-taking.
Risks
- High volatility in share price as evidenced by the price difference between the purchase ($0.153) and sale ($0.123) within a 24-hour period.
Future Outlook
No specific forward-looking guidance provided in this regulatory filing.
Industry Context
StockSavvy.ai notes that institutional trading activity in micro-cap biotech stocks like Clearmind Medicine often reflects liquidity management or algorithmic trading strategies rather than fundamental shifts in corporate strategy.
Comparison to Industry Standards
- The transaction volume is consistent with standard institutional portfolio rebalancing for small-cap equity holdings.
Stakeholder Impact
- Shareholders should note the increased institutional activity which may impact short-term stock liquidity and price volatility.
Next Steps
- Monitor future Form 4 filings to determine if HRT Financial LP continues to accumulate or divest shares.
Key Dates
| Date | Description |
|---|---|
| 06/10/2026 | Date of initial purchase of 2,159,052 shares. |
| 06/11/2026 | Date of sale of 225,191 shares. |
| 06/12/2026 | Date of filing signature. |
Recommendation
holdThe filing reflects routine institutional trading activity. Investors should wait for fundamental business updates or clinical trial results from the company before adjusting positions based on this transaction.
Keywords
Clearmind Medicine, CMND, HRT Financial LP, Insider Trading, Form 4, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.